Related Experiment Video
Updated: Aug 10, 2026
08:32
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
Tumour localisation by human monoclonal antibodies
Medical Oncology and Tumor Pharmacotherapy
|January 1, 1985
Summary
Human monoclonal antibodies show promise for detecting solid tumors. Researchers successfully used these antibodies to localize glioma and bronchial carcinoma in patients, demonstrating their clinical potential.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Human monoclonal antibodies (mAbs) offer targeted therapeutic and diagnostic potential in oncology.
- Developing human mAbs presents technical challenges but is crucial for clinical applications.
Purpose of the Study:
- To evaluate the clinical utility of human monoclonal antibodies for the localization of solid tumors.
- To assess the efficacy of specific human mAbs in patients with glioma and bronchial carcinoma.
Main Methods:
- Human lymphocytes from cancer patients were fused with a human lymphoid line to generate hybridomas.
- Two selected human mAbs (LGL1.1D6 and LLU6.3A4) were purified and radiolabeled with Iodine-131.
- Radiolabeled mAbs were intravenously administered to patients with advanced glioma and bronchial carcinoma for imaging.
Main Results:
- Successful tumor localization was achieved in 5 out of 8 patients with glioma.
- Tumor localization was successful in 5 out of 7 patients with bronchial carcinoma.
- The study demonstrated good localization patterns in a significant proportion of patients.
Conclusions:
- Human monoclonal antibodies have demonstrated potential for the clinical localization of solid tumors.
- Despite production challenges, human mAbs are a viable tool for cancer diagnosis and imaging.
- Further development of human mAb technology could enhance cancer patient management.
